Page 252 - Medicinal Chemistry Self Assessment

Index 241

Methylation, 70, 197 Phenol, 185 Serotonin receptor modulator, 31, 137
Mevalonic acid, 74, 207-208 Phenylalanine, 88, 228 Serotonin reuptake transporter (SERT), 51,
Montelukast, 69-70, 193-198 Phenytoin functional groups, 3, 37 169
Morphine, 23, 123 Phosphate salt, 84, 224 Serotonin selective reuptake inhibitors
(SSRI), 51, 169
pK , 71, 201
a
N range, 6, 31, 73, 75-76, 91, 101-102, Shitaki mushrooms, 20, 116
N-acetylsialic acid, 91-92, 234-235 137, 206-207, 211-212, 233 Short-acting agent, 71, 200
Natamycin, 12, 106-107 values, 42, 69, 154-155, 193, 194-195 Sitagliptin, 83-85, 223-226
Sodium salt(s), 70, 71, 195, 200
N-dealkylated monoethylglycinexylidide, Plasma pH, 11, 14, 105, 109
67, 192 Plasma protein binding, 30, 32, 41-42, 70, Solubility, 13-15, 109-112
Neostigmine bromide, 81, 219-220 84, 134-135, 139, 153, 197, 225 Sorafenib, 87-89, 227-231
Nerolidol, 19, 115 Potassium salt, 13-14, 109 Sorbinil, 7-8, 99, 101, 102
Neuraminidase, 91, 234-235 Pravastatin, 9, 73-74, 103, 205-209 Stereochemistry, drug action and, 21-22,
117-121
Nifedipine, 21, 117-119 Primarily ionized, 11, 105-106 Steroid-based hormone, 62, 185
Nilotinib, 88-89, 229, 231 Primarily unionized, 11, 105-106
Nitrofurantoin, 11, 105-106 Primary amine, 185 Stomach pH, 11, 14, 105, 109
Sulfamethoxazole, 4, 96
Nonelectrolyte, 9, 103 Prodrug(s), 44, 48, 60, 76, 161-162, 174,
180-181, 212 Sulfate conjugation, 23, 56, 123, 176
Non-hydrolyzable hydroethylene, 30, 134
Non-peptidomimetic prodrug, 44, 161 Protein tyrosine kinases, 87-89, 227-231 Sulfonamide, 194
Pyridyl nitrogen, 89, 230 Sulfonylureas, 41-42, 153-157
Norepinephrine reuptake, 24, 125
Nucleophilic side chain, 38, 147 Q T
O Quinapril, 75-78, 211-215 Taste receptors, 20, 116
Quinaprilat, 76-77, 212-213 Tetracycline, 13-14, 109
Odorant molecules, 19, 115
Tetrapeptide side chains, 5, 98
Oral anticoagulant, experimental, 7-8, 99, R
101, 102 Thrombin active site, 43, 159
Oral bioavailability, 52, 171 R-A double bond reduction, 58, 179 Thrombin inhibitor, 43, 159
Oseltamivir, 91-92, 233-237 Ranitidine, 12, 108 Thyroglobulin molecules, 61, 183
Oxidative N-dealkylation, 56, 142, 176 Reactions, 58-59, 179 Tocainide, 67, 192
Oxidative O-dealkylation, 48-49, 70, 92, Reduction, 56, 176 Tolbutamide, 32, 41, 139, 153-156
168, 198, 236, 237 R-enantiomer, 62, 84, 184, 224-225 Tolterodine, 18, 114-115
Oxidative transformation, 28-29, 132-133 Renin, 30, 134 Tolycaine, 67, 192
Oxybutynin, 18, 114-115 Resonance, 4, 55, 79, 96, 217 Tosylate salt, 89, 231
Ring A ketone reduction, 58, 179 Transformations, 58-59, 179
P Rivastigmine, 79-81, 217-221 Tricyclic antidepressant, 24, 124

Passive diffusion, 89, 231 Routes of administration, biological targets Tri-iodo-L-thyronine (T ), 61, 63, 183, 185
3
Penicillins, 38, 147 and, 14-15, 109-110 Tyrosine, 98
Peptide cleavage, 76, 213 Rule of Nines, 12, 69, 106, 194 Tyrosine kinase inhibitor, 87-89, 227-231
Peptide-based hormone, 62, 185 S
pH/pK , 11-12, 105-106 U
a
Phase I transformation, 23-24, 33, 37, Salmeterol functional groups, 3, 37 Umami receptor, 20, 116
40, 48, 53, 56, 66-67, 70, 72, 85, 92, Salts, 13-15, 109-112 Unionized, 31, 36, 55, 69, 71, 75-76, 91, 137,
123-125, 141-142, 146, 150-151, Scents, 19, 115 145, 174, 193-194, 201, 211-212, 233
167-168, 172, 175-176, 191-192, Sclareol, 19, 115 Urinary pH, 11, 105
197-198, 202, 226, 236-237
Scopolamine, 14, 109-110
Phase II transformation, 23, 33, 37, 40, 48, V
56, 70, 72, 92, 123, 125, 141, 146, Secobarbital, 71, 199-200, 201
151, 167-168, 175, 197, 202, 236-237 metabolite, 72, 202-203 Valine, 87, 98, 227
Phenobarbital, 71-72, 199-203 S-enantiomer, 62, 184 Van der Waals, 19, 87, 114-115, 140, 196,
metabolite, 72, 202-203 Serine, 79, 80, 218-219 202-203, 227